Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1999 Oct 26;96(22):12691–12696. doi: 10.1073/pnas.96.22.12691

Activation changes the spectrum but not the diversity of genes expressed by T cells

T Kent Teague *,, David Hildeman ‡,, Ross M Kedl ‡,, Tom Mitchell *,, William Rees *, Brian C Schaefer , Jeremy Bender *, John Kappler ‡,§,¶,‖, Philippa Marrack ‡,§,¶,**,‡‡
PMCID: PMC23052  PMID: 10535984

Abstract

During activation T cells are thought to change their patterns of gene expression dramatically. To find out whether this is true for T cells activated in animals, the patterns of genes expressed in resting T cells and T cells 8 and 48 hr after activation were examined by using Affymetrix gene arrays. Gene arrays gave accurate comparisons of gene expression in the different cell types because the expression of genes known to vary during activation changed as expected. Of the approximately 6,300 genes assessed by the arrays, about one-third were expressed to appreciable extents in any of the T cells tested. Thus, resting T cells express a surprisingly large diversity of genes. The patterns of gene expression changed considerably within 8 hr of T cell activation but returned to a disposition more like that of resting T cells within 48 hr of exposure to antigen. Not unexpectedly, the activated T cells expressed genes associated with cell division at higher levels than resting T cells. The resting T cells expressed a number of cytokine receptor genes and some genes thought to suppress cell division, suggesting that the state of resting T cells is not a passive failure to respond to extant external stimuli.

Keywords: activated, resting, gene array


A good deal of attention has been paid to gene expression in differentiated T cells of various types. Subtraction techniques, differential display, and gene array analysis all have been used to investigate differences in gene expression between different kinds of T cells (16). Most of these experiments have been performed by using established T cell lines, or at least T cells that have been withdrawn from their host and cultured for some time. Relatively few experiments have addressed the question of overall gene expression in T cells in animals. Because of this there are significant holes in our knowledge of these cells. For example, little is known about gene expression in resting T cells. Gene expression in resting T cells is not, however, an uninteresting problem. Although for many years it was thought that resting T cells were in a quiescent stage, existing independently of their surroundings, recent experiments have shown that this is far from true. The survival of small, naïve resting T cells in animals depends on receipt of many life-preserving factors from their environment. For example, the life expectancy of these cells is known to be dependent on low-affinity engagement of their antigen receptors by the MHC protein and probably the peptide that drove their selection in the thymus (710). For their survival, small, resting T cells in animals probably also depend on engagement of cytokines such as IL-6 and IL-7 (1115).

The appearance of antigen or superantigen in animals leads to the rapid activation of specific T cells. These activated cells divide rapidly and then many of the progeny of the dividing cells die within a few days (16, 17). This phenomenon does not occur if the T cells are activated in vitro. Therefore, an understanding of the ways in which activated T cells die in animals depends on activating the cells in vivo, not in vitro.

This paper describes our attempts to deal with these deficiencies in our knowledge. mRNA was purified from resting T cells, or T cells that recently had been activated. Analysis was performed by using Affymetrix gene arrays (Santa Clara, CA). The results showed that resting T cells expressed a surprisingly large diversity of different mRNAs. Within 8 hr of activation in vivo the range of genes expressed by the T cells changed dramatically, although the total number of genes expressed did not change. Two days after activation, the spectrum of genes expressed by the activated cells was much more like that of resting T cells. However, again, the total number of different genes expressed was still about the same, amounting to about one-third of all the genes on the array. Comparison of the genes expressed by resting T cells with T cells 48 hr after activation showed that the latter cells expressed, not surprisingly, many genes associated with cell division. Among the genes expressed at higher levels by resting cells were those coding for a number of cytokine receptors and for several genes thought to inhibit cell division. Hence, the state of resting T cells may depend on active processes that allow the cell to be nurtured by its environment and actively prevent it from entering cell division.

Materials and Methods

Mice and Cells.

T cells were activated in C57BL/10 mice (The Jackson Laboratory) by i.v. injection of 150 μg of the Vβ8.x-specific superantigen, staphylococcal enterotoxin B (SEB; Sigma). This procedure generates T cells bearing Vβ8.x that are fully activated as judged by the fact that, 8 hr later, they all bear CD69 and, 18 hr after injection of SEB, all the Vβ8.x+ T cells begin to divide (ref. 17; unpublished observations). One group of mice was sacrificed 8 hr after injection of SEB. Another group of mice was sacrificed 48 hr after injection of SEB, at the time when the SEB-stimulated T cells had reached their maximum numbers and just before they were to start to die (17). Lymph nodes were harvested from these animals and from control, untreated mice, and T cells prepared by passage through nylon wool columns (18). To purify the T cells more thoroughly, the cell preparations were stained and sorted by using a MoFlo Instrument (Cytomation, Fort Collins, CO). Normal resting T cells were isolated from nonimmunized mice after staining with phycoerythrin (PE)-labeled anti-Cβ, CyChrome-labeled anti-CD4 and anti-CD8, and fluorescein (FL)-labeled anti-IAb and anti-CD69 (PharMingen). Sorting gates were set to collect small Cβ+ cells bearing CD4 or CD8 and to exclude cells bearing IAb or CD69. Sorted cells were analyzed on a FACScan cytofluorograph (Becton Dickinson) to assess their purity.

Activated T cells were isolated from mice previously injected with SEB. Lymph node cells from these animals were passed over nylon wool columns, and these T cell-enriched preparations were sorted to isolate the activated, Vβ8.x-bearing cells after staining with PE-anti Vβ8.x, CyChrome anti-CD4 and anti-CD8, and FL-anti-IAb. Sorting gates were set to include Vβ8.x+ cells bearing CD4 or CD8 and to exclude cells bearing IAb. This procedure thus isolated SEB-stimulated Vβ8.x+ T cells and excluded resting T cells, B cells, and dendritic cells. As above, the effectiveness of the procedure was checked by analysis of the staining profile of the sorted cells. The characteristics of the various sorted cell populations are shown in Table 1. More than 97% of the cells in all three populations bore Cβ (resting T cells) or Vβ8.x. The populations were contaminated with 0.7% or less B cells, dendritic cells, and class II+ macrophages. Residual cells in the SEB-activated populations were resting T cells that bore β other than Vβ8.x (data not shown).

Table 1.

Characteristics of materials used in gene array experiments

T cell type No. of cells sorted % cells bearing Cβ or Vβ8.x % cells bearing IAb Yield RNA, μg μg RNA/107 cells
Resting 13.9  ×  107 99.6 0.4 115 8.2
8-hr activated 2.7  ×  107 98.6 0.7 38 14.1
48-hr activated 6.9  ×  107 97.4 0.5 136 20.0

RNA was isolated from these cells by using rapid total RNA isolation kits (5 Prime → 3 Prime). Between 8.2 and 20 μg of total RNA was isolated per 107 cells from the various populations (Table 1). Poly(A)+ mRNA was purified from each of the preparations by using Oligotex mRNA minikits (Qiagen). The quality of the poly(A)+ mRNA was evaluated on the Affymetrix Gene Arrays as described below.

Preparation of cRNA and Gene Chip Hybridization.

cDNA was synthesized from the poly(A)+ mRNA by using SuperScript Choice kits (GIBCO/BRL) and nucleotide primers that contained a sequence recognized by T7 RNA polymerase. cRNA was prepared in an in vitro transcription reaction by using T7 polymerase (MegaScript T7 kit; Ambion, Austin, TX). The quality of the cRNA prepared from the cells was evaluated by control hybridizations with probes built to match the 5′, middle, and 3′ sequences of β actin, glyceraldehyde phosphate dehydrogenase, and 18S RNA. For all three preparations of cRNA the signals obtained for different regions of the same gene were about the same, i.e., the cRNA contained intact coding sequences. Also, the signals obtained by hybridization to 18S RNA were comparatively low, demonstrating that the poly(A)+ mRNA from which the cRNAs were prepared were relatively pure (data not shown). The cRNAs were not significantly contaminated with the products of B cells, dendritic cells, or macrophages because their cRNAs gave little or no signal with probes for Ig, class II MHC, or macrophage-specific proteins, with the exception of class II IEβ (http://www.kmlab.njc.org).

Results

Normalization of the Measurement of Gene Expression in Resting and Activated T Cells.

Both 8- and 48-hr activated T cells contained about twice as much total RNA, and probably about the same amount more poly(A)+ mRNA, than resting T cells (Table 1). However, activated T cells are much larger than resting T cells; therefore, a doubling in the amount of a particular mRNA does not indicate a doubling in the concentration of that mRNA, or the protein it codes for, in the activated cell. For many proteins, concentration is probably more significant than total number of molecules per cell. Therefore, in the discussions below, we chose not to consider the fact that the bulk amount of RNA was increased between resting and activated cells. Rather, we evaluated the concentration of a given mRNA in a sample relative to the entire pool of poly(A)+ transcripts in that pool. To accomplish this, the gene chip signals were normalized to an overall signal, the average of signals for each cRNA preparation on each chip, before analysis.

Anaylsis of Overall Gene Expression in Resting and Activated T Cells.

RNA transcript levels for different genes were assessed by using Affymetrix software. The relative abundance of a particular mRNA was expressed as the “average difference.” This is calculated from the difference in fluorescence intensity given by a labeled RNA sample when hybridized to oligos built to match a particular gene sequence vs. when hybridized to oligos mismatched by one base. To get an overall impression of the differences in gene expression between the different types of T cell we plotted the values for average differences obtained for each gene in each type of T cell against their values in the other cells (Fig. 1). Gene expression between resting and 8-hr-activated T cells was quite different as indicated by the scatter in the points on Fig. 1A. Differences in average differences of more than 2-fold for a particular gene between two samples of RNA from different cells are, in general, likely to reflect real differences in gene expression (Affymetrix). Many genes in resting and 8-hr-activated T cells differed by at least this much as indicated in Fig. 1A by the points that lie outside the lines drawn to show 2-fold differences in level. The overall correlation coefficient for Fig. 1A is low, at less than 0.79. Interestingly, the number of genes whose expression decreased upon activation was as large as the number of genes whose expression increased. Hence, transcriptional inhibition in activated T cells was unexpectedly frequent (30).

Figure 1.

Figure 1

Comparison of gene expression in resting and activated T cells. Poly(A) RNA was prepared and converted into fluorescent-labeled cRNA as described in Materials and Methods. The levels of cRNAs derived from different genes were measured by using Affymetrix Gene Arrays and expressed as average differences. The plots compare genes that had average differences greater than 50 in the T cell type against which the comparisons were made. Genes with average differences ≤0 in the index T cell type were omitted from the analyses. These were 57 genes in A, 53 genes in B, and 78 genes in C. The lines drawn on the graphs represent differences in average difference of 2-fold between the two samples considered. (A) Comparison of average differences for gene expression in T cells 8 hr after activation and resting T cells, with 2,758 genes considered. (B) Comparison of average differences for gene expression in T cells 48 hr after activation and resting T cells, with 2,762 genes considered. (C) Comparison of average differences for gene expression in T cells 48 hr after activation and 8 hr after activation, with 2,592 genes considered.

Comparison of overall gene expression between resting T cells and T cells 48 hr after activation with SEB in mice showed fewer differences. Fewer genes differed in average differences by more than 2-fold, and the correlation coefficient was higher, at greater than 0.92. Again, some genes were expressed at higher levels in 48-hr-activated cells than in resting T cells and vice versa (Fig. 1B).

Not surprisingly, given the data in Fig. 1 A and B, T cell gene expression also was quite different when data from cells 8 hr after activation and 48 hr after activation were compared (Fig. 1C). The significance of differences in gene expression in two samples of mRNA was calculated by Affymetrix software by using a combination of actual values of the average differences for that gene in the two samples and the value of the subtraction of the average differences. The parameter thus derived is called the sort score.

To get an overview of the differences in gene expression between resting and activated T cells, we counted the numbers of genes in each comparison that had sort scores greater than 2 in such comparisons and an average difference value in the higher-expressing tissue greater than 100. This cutoff gave a conservative estimate of the numbers of genes that actually changed their expression levels between resting and activated T cells. The results are shown in Table 2. Also shown in Table 2 is the number of RNAs in each sample that had average difference scores of greater than 100.

Table 2.

Activation changes the spectrum but not the diversity of genes expressed in T cells

T cell type
Resting 8-hr activated 48-hr activated
No. genes with average 2,057 1,852 2,056
 differences >100
No. genes increased* 143 36
No. genes decreased* 139 15
*

Genes noted had average differences in the higher-expressing T cells >2 and sort scores ≥2 and are compared with their level in resting T cells. 

These data confirm the impression given by Fig. 1. All three types of T cells expressed about the same number of RNAs with average difference scores of greater than 100. RNA expression between resting and 8-hr-activated cells was quite different, with about 280 of the 6,319 genes evaluated as being significantly differently expressed, some expressed more highly in activated cells, and some expressed at greater levels in resting cells. There was much less difference between 48-hr-activated and resting T cells with only 51 genes differing, at this level of sensitivity, in their level of expression. Thus, shortly after exposure to antigen in animals, target T cells dramatically change their mRNA composition. At later times this pattern returns to a composition that is much closer to, but not the same as, that of resting T cells.

Comparison of Individual Gene Expression in Resting and Activated T Cells.

Individual genes were evaluated to find out whether changes in gene expression were consistent with expectations. Signals for housekeeping genes such as HPRT and β-tubulin were unaffected by activation. The levels of CD3, CD4, and CD8 proteins in T cells are known to be unchanged by activation, and the expression of their genes likewise was unaffected. On the other hand, expression of the α-chains for both the IL-6 receptor and IL-7 receptors was reduced at the protein level by activation, and the levels of expression of the genes for these proteins, as detected by the Gene Arrays, also was reduced in activated samples. Finally, surface expression of the α-chain of the IL-2 receptor was transiently increased and that of CD62L was transiently decreased during activation, a result that mirrored the RNA expression data (http://www.kmlab.njc.org; and data not shown).

Occasionally there were discrepancies between the protein and gene expression data. For example, the Gene Array data indicated that expression of the gene for the IL-2 receptor β-chain increased after activation. Levels of this protein on the surface of T cells did not increase, however, until 48 hr after activation. This discrepancy may be because protein synthesis and expression on the cell surface will always, of course, be delayed by comparison with mRNA induction. Thus, for the IL-2 receptor β-chain, 8 hr of activation may have been early enough to observe mRNA induction but too early to observe increases in surface protein. Similarly, mRNA for CD62L fell precipitously by 8 hr after T cell activation. However, cell surface levels of the protein were only halved at this time, again demonstrating a significant temporal delay in levels of protein consequent to changes in mRNA level (http://www.kmlab.nationaljewish.org; and data not shown).

The results for genes that changed in expression level more than 2-fold and that had average differences of greater than 100 in the higher-expressing tissue, between resting and 48-h-activated T cells, are shown in Tables 3 and 4. Expressed sequence tags (ESTs) were omitted from this list because, in our experience, data from ESTs do not necessarily represent values for the gene to which they are thought to be similar.

Table 3.

RNAs increased in 48-hr-activated vs. resting T cells

Accession no. Description Average differences
Resting 8-hr activated 48-hr activated
Extracellular matrix and cell adhesion
X16834 Carbohydrate-binding protein, Mac-2 110 71 271
U08020 Alpha-1 Type 1 collagen 60 176 175
U25652 Alpha-1 Type XII collagen 41 44 127
L24430 Osteocalcin precursor, gla protein 103 16 244
D00622 Heparin-binding protein 44 86 41 221
Cell surface receptors/transporters/proteins
X71788 Blr-1, receptor for chemokine BLC 34 86 123
X85214 Ox40 238 1,481 637
X05719 CTLA-4 831 1,477 3,706
X98113 CD4-like cell surface glycoprotein 4 184 235
X04653 Ly-6E.1 781 5,881 1,951
M99377 Alpha-2 adrenergic receptor 43 18 125
M63436 GABA-A receptor alpha-1 subunit 20 43 119
L01776 Neuronal calcium channel 42 41 132
U65593 K+ channel beta 4 subunit 39 54 147
Cell structure/vesicle movement/secretion
W29468 Myosin light chain 2 29 178 147
X97650 Myosin 1 103 43 293
W13586 Atrial/fetal myosin light chain 35 2 186
X54511 Mbh1, gelsolin actin-binding protein 190 93 448
M26251 Vimentin 2,172 537 4,810
D12646 kif4, kinesin-like protein 47 37 135
Y09632 Kinesin-like protein 174 33 30 190
M16455 Calpactin-1 light chain (p11) 1,586 336 4,362
D10024 Calpactin-1 heavy chain 143 110 1,086
U66865 Vacuolar protein-sorting hom. (VPS45) 35 58 126
M62418 Clathrin-associated protein 19 (AP19) 143 188 333
L33726 Fascin 17 19 117
W29418 Fast skeletal troponin C 36 32 152
Signal transduction
U03856 CD45-associated protein (cd45-ap) 1,294 1,304 2,640
U28168 Familial adenomatous polyposis 287 285 677
D00208 S100A4 + Ca2+-binding protein, pEL98 311 61 802
AA120244 S100 Ca2+-binding protein, A13 553 142 1,292
X66449 Calcyclin −33 −122 338
M19380 Calmodulin (Cam III) 324 389 929
X65138 Eph-related receptor tyr kinase −23 50 122
U38196 Mpp-1 82 61 218
Chromatin and nuclear structure
X12944 HMG-17 chromosomal protein 2,015 2,553 4,436
X58069 Histone H3.2-F, H2a.1-F H2b-F 222 319 725
X16705 Iamin B 89 75 558
Z46757 High mobility group 2 protein 1,606 1,106 6,829
Cell division
X62154 P1 protein (P1.m) 45 282 147
D13545 Primase large subunit −7 61 113
J04620 Primase small subunit 78 290 308
D17384 DNA polymerase α subunit 1 42 105
D12513 DNA topoisomerase IIα 50 55 355
U19604 DNA ligase I 23 75 212
D86726 mMIS5 426 1,113 1,116
D13473 RecA-like protein MmRad51 −3 24 141
L26320 Flap endonuclease-1 (FEN-1) 19 187 141
Z26580 Cyclin A 96 80 561
X64713 Cyclin B 10 17 123
X66032 Cyclin B2 37 19 653
X75888 Cyclin E 105 142 215
U63337 Cyclin-dependent kinase-2α 41 107 185
D26091 mCDC47 572 1,387 1,488
U58633 p34 CDC2 + B68 19 −5 555
U20497 Cdk4 and Cdk6 inhibitor p19 177 −30 491
D21099 Stk-1 10 −12 206
u50378 Ku70 59 281 165
K02927 Ribonucleotide reductase M1 157 323 541
X15666 Ribonucleotide reductase M2 74 27 263
W08120 Thioredoxin 2,142 7,378 6,254
X77731 Deoxycytidine kinase 35 28 178
M68489 Cytosolic thymidine kinase −79 −61 347
M13019 Thymidylate synthase −38 132 640
M63445 Methylenetetrahydrofolate DeH 65 234 139
L08266 Fanconi’s anemia complementation 23 49 104
X14805 Cytosine-5-methyltransferase 116 146 314
Transcription
X61385 T cell transcription factor, TSF1 526 730 1,234
Z54283 Oct-binding factor 1 42 46 138
M16449 Myb 338 254 845
X70472 B-Myb −8 44 158
X72310 DRTF-polypeptide-1 69 425 224
M83380 RelB 86 152 187
U19 799 IkB-β 53 357 125
M36146 Zfp-35 33 14 110
X72697 Xmr meiosis-regulated protein 179 258 464
U32394 Mad3 59 20 134
U46187 KRAB + Zinc finger protein 1 13 104
U41741 USF 51 94 135
Y07836 Basic helix–loop–helix protein 74 291 225
M13018 Cysteine-rich intestinal protein (CRIP) 90 −28 226
D26090 Hox-3.1, Hox 3.2-Hox-3.1 intergenic region 353 1,107 1,250
M75953 Homeobox+, PMUR10F 28 28 137
M34857 Hox-2.5 17 5 125
U52951 Putative transcrip., reg., mEnx-1 59 349 348
Protein synthesis/degradation
U39302 26S proteosome sub. 4 ATPase 233 783 484
W11011 Ubiquitin-like protein −147 172 121
U48830 Subtilisin-like convertase-7 96 44 218
Glycolysis/ATP production
M32599 Glyceraldehyde-3-phos. DeH 2,571 3,730 5,162
X53333 Triose phosphate isomerase 375 2,723 1,399
AA028501 Cytochrome c oxidase VIII-H 14 −16 105
Redox control/control of oxidation damage
X82067 Thioredoxin-dep. peroxide red’ase 315 684 657
D49956 8-oxo-dGTPase 88 252 177
X61147 Iron-responsive element-binding protein 52 113 132
M68896 Androgen-regulated protein, arMEP24 44 14 119
U48420 Theta class glutathione transferase type 2 −34 −20 113
Cell life and death
L16462 A1, Bcl2-like protein 583 510 1,257
U54803 Caspase 3 85 86 719
L37296 BAD 12 54 115
X95591 C1D 65 33 136
X73985 Calretinin 122 141 331
Secreted products
X86374 TAG7, TNF-like cytokine 147 35 335
X04072 Granzyme B 12 3,561 238
M13226 Granzyme A 88 336 763
X53257 Neurotrophin 3 23 −2 171
AA124831 Eosinophil second. gran. protein  (mEAR-2) 80 80 198
X04573 Preproelastase 67 60 140
X04574 Preprotrypsin 61 34 213
D00466 Apoplipoprotein E 78 98 160
J02644 Type 1 epidermal keratin 88 83 186
Miscellaneous
M23236 Proline-rich protein (MP-2) 55 135 148
L21027 A10 209 1,307 463
U69488 Viral envelop-like protein (G7e) 80 48 415
M34897 Ecotropic viral integration site 2 ORF 39 −103 121
M21332 RNA-binding protein 1 196 212
M26270 Stearoyl-CoA desaturase (SCD2) 94 311 437
U42385 FGF-inducible gene 16 (FIN16) 34 87 195
D21099 Putative ser/thre kinase, Stk1 10 −12 206
U10484 Lymphoid membrane protein, Jaw1 46 220 938
W13002 β-galactosidase-binding protein 526 91 4,460
X82786 Ki-67 (MIB1) 36 21 895
L42293 Acyl CoA:cholesterol acetyltrans’ase 72 95 152
U13837 Vacuolar ATPase subunit A 38 80 101
U232332 p13MTPC1 −7 12 134
X58523 MIPP 45 28 105
X06917 Aspartate aminotransferase 250 700 547
J03857 B 29 56 23 114
L09192 Pyruvate carboxylase homo. protein 1 70 139

Table 4.

RNAs decreased in 48-hr-activated vs. resting T cells

Accession no. Description Average differences
Resting 8-hr activated 48-hr activated
Extracellular matrix and cell adhesion
U12236 α M290 integrin, binds β7 integrin 530 53 253
X64550 RHAMM, hyaluronan receptor 111 66 40
X84037 E selectin ligand-1 119 107 54
X58251 Pro-alpha-2(1) collagen 174 11 52
D00613 Matrix Gla protein 108 38 23
Cell surface receptors/transporters/proteins
M27960 IL-4 receptor 1,634 519 559
M29697 IL-7 receptor α-chain 897 83 228
X53802 IL-6 receptor 549 70 271
U69599 IFNγ receptor second chain, ifngr2 383 203 104
D63679 Decay accelerating factor 255 28 91
U36757 Thrombin receptor 120 96 56
X62701 Urokinase-type plasminogen acti R 111 180 17
X99581 Leucocyte 7 transmembrane R 1,411 557 396
X15643 β-2-Adrenergic receptor 139 33 42
X62600 α-1-Acid glycoprotein, AGP/EB 318 157 27
X61433 Na/K ATPase β-subunit 649 184 241
D78572 LIG-1 145 77 60
D83206 p24 164 70 70
U49720 Blue cone pigment 246 90 39
X81582 IGF binding protein 4 1,077 1,029 −54
U35836 Tumor-ass. glycoprotein E4, Tage4 111 14 −25
X85992 Semaphorin C 134 40 55
Cell structure/vesicle movement/secretion
AA123361 Rab6/rab5-ass. protein, rab6 2,940 961 1,205
M13444 α-Tubulin isotype M-α-4 1,315 1,448 629
Signal transduction
X02452 Ki-ras 368 120 142
M63630 GTP-binding protein, IRG-47 292 462 112
U19119 G protein-like LRG-47 221 284 66
U15636 U2, T cell GTP-binding protein 915 605 155
X51829 MyD116 2,998 924 1,286
Y08361 RIL 175 7 −12
U38252 Proline-rich RING finger protein 926 631 330
X63039 RSP-1 257 138 114
U58497 Mnb protein kinase, Dyrk 183 59 80
U58885 SH3-containing protein SH3P8 131 125 26
U58882 SH3 domain-containing protein, Lasp-1 133 −45 28
U58512 Rho-associated protein kinase 108 44 45
U56909 Tousled-like kinase 123 85 49
L01695 Calmodumin-dep. p.diesterase, PDE1B 254 73 54
M96163 Serum-inducible kinase, SNK 130 33 39
U18310 SEK1 123 70 34
Chromatin and nuclear structure
X70887 Protein like transition protein 2, TP2 752 1,597 349
U62673 Histones H2a(A)-613, H2a(B)-613, H2b-613 103 87 31
J03482 Histone H1 273 55 130
U40796 DNA repair enzyme, ERCC5 224 34 80
Cell cycle
U44426 D52, cell cycle inhibitor 161 180 80
Z14986 S-Admethionine decarbox’ase 1,314 728 601
Transcription
U25096 Kruppel-like factor LKLF 5,727 583 1,754
U70662 Kruppel-like factor EZF, Zie 708 529 155
U36340 BKLF 389 101 184
U06924 STAT1 1,468 873 437
J03236 junB 11,687 2,121 5,821
J04115 c-Jun 234 25 −25
X14897 FosB 514 235 151
X98096 Transcription factor BFCOL1 1,195 286 567
X62940 TSC-22 237 50 68
M58564 TIS11 552 311 241
U73329 Dix7, Distal less homeobox gene 158 60 60
M82974 Hen1 127 59 37
U28071 Hoxc-5 105 20 36
U20282 Stromelysin PDGF-resp. elem binding ? 277 121 94
X61753 Heat shock transcription factor 1 140 350 14
U13878 Neural-restrictive silencer factor 174 60 85
M34476 Retenoic acid receptor gamma-A 198 61 82
Protein production and degradation
W13646 Polyubiquitin, TI-225 3,991 12,610 1,170
Z19579 slah-1A 314 81 52
L40406 Heat shock protein 105 kD β 1,343 2,599 451
U63323 Translation init. factor, Eif4g2 1,532 1,187 726
U70674 B2 element and 18S RNA seq. 122 7 2
U16162 Prolyl-4-hydroxylase alpha-1 143 204 65
U35646 Aminopeptidase 171 35 75
Cell life and death
U43678 Ataxia telangiectasia gene 106 76 21
Intermediary metabolism
X85983 Camitine acetyl transferase 138 67 64
U53142 Constitutive nitric oxide synthase 113 −10 −36
X51905 Lactate dehydrogenase-B 141 55 57
U00978 Type 1 inosine monophosphate DeH 261 596 130
Secreted products
L38580 Galanin 106 55 14
M11943 Wnt-1 2,334 145 107
X96618 Stromal cell protein-inducing RAG 431 184 181
Miscellaneous
M64292 TIS21 1,623 317 305
V00727 Replication-defective murine sarcoma virus 3,956 643 1,209
U34072 Steroid DeH, Ke 6, Ke 6a, Ke 6b 343 24 110
U43085 Glucocorticoid-atten. resp. gene 39,  GARG-39 197 30 54
D30785 Neuropsin, serine protease 575 146 276
x96639 EXT1, analog of human multiple exostosis 173 46 33
M29011 Immunoglobulin α-chain switch region 123 −36 27
D87744 Atrophin 1 (DRPLA) 157 48 73
U42386 FIN14, FGF-inducible gene 1,259 564 565
X59379 Nexin II, amyloid beta precursor 102 16 13
X67140 SR calcium ATPase 227 175 110
M21532 PCD-5 188 65 79
X57199 Lysosomal acid phosphatase 429 206 82
Z46720 Perinuclear-bind. protein, PICK-1 159 −26 18
M10021 Cytochrome P1-450 113 22 −8

Many genes contributing to cell division were expressed at higher levels in activated vs. resting T cells, as expected. These included the genes for DNA polymerase and primase, for the cyclins, and for many of the enzymes involved in synthesis of DNA precursors. Eight-hour-activated T cells contained higher levels of mRNA for cyclins D and G1, presaging their entry into mitosis about 16 hr later. Forty-eight-hour-activated T cells contained elevated levels of mRNA for cyclins A1, B, and E. Also increased in activated cells were mRNAs for Myb and Myb-B, DNA-binding proteins involved in the stimulation of cell division (refs. 19 and 20; Table 3).

Conversely, some genes that are expressed preferentially in nondividing cells and/or whose products are thought to prevent cell division were expressed at higher levels in resting than activated T cells. Included in these were the genes for the retinoid acid receptor RAR, Dyrk, a protein involved in terminal differentiation and cessation of proliferation, and the proliferation inhibitory transcription factors D52 and TSC-22 (refs. 6 and 2123; Table 4).

There were large changes in expression of other transcription factors. For example, as reported previously, resting T cells expressed the gene for the Kruppel-like transcription factor, LKLF, at higher levels than activated T cells (ref. 24; Table 4) Less expected was the fact that this also applied to other Krueppel-related transcription factors, EZF and BKLF. Also noteworthy was the increased expression of RelB (19, 25) and IkB-β and several Hox genes in activated cells.

Many papers have shown that members of the Fos/Jun family are very important inducers of gene expression in activated T cells (26). Others have shown that expression of these genes is changed during T cell development, increased upon T cell activation, and decreased in anergic cells (2729). The analysis in this paper and in a previous report (30) showed a dramatic lowering in levels of mRNA for proteins of the Fos/Jun family and for one of the kinases upstream of activation of these proteins, SEK1. These results suggest that the function of this branch of the MAP kinase signaling pathway may be significantly curtailed in activated T cells.

mRNAs coding for some of the secreted products of T cells, such as the granzymes, increased as the cells were activated. Surprisingly, however, it appeared that resting T cells also make transcripts for some secreted proteins. Overall, the decrease in expression of one of the integrins and a ligand for E-selectin and the increase in expression of enzymes such as trypsin and elastase, which could be involved in tissue penetration, gave the impression that, as is known to occur, the activated T cells were preparing themselves for greater mobility than their resting precursors.

Finally, there were several examples in which expression of a gene in resting T cells appeared to be replaced by expression of a related gene in activated T cells. For example, activated T cells contained more mRNA for Alpha 2 type I collagen and for the transcription factor BFCOL1, which activates this gene (31), and less mRNA for Alpha 1 types I and XII collagen than resting T cells. Likewise, expression of genes related to the basement membrane-binding proteins osteocalcin and matrix Gla protein seesawed in the two types of T cells, as did genes for some of the Hox proteins.

Discussion

Recently, immunologists’ view of the resting T cell has undergone a revolution. Our data and other recent reports have demonstrated that the resting T cell is constantly receiving signals from its environment in the animal. These signals help to keep the cell alive and to guide the cell to various locations (714, 32). Given this new appreciation of the activity of resting T cells it perhaps is not surprising to find that mRNAs for many different proteins are expressed at detectable levels in these cells, a result that has been suggested before (30).

Among the factors that are detected by resting T cells, and that help to keep them alive, are IL-4 and IL-7 (1214). IL-4 also can stimulate the proliferation of activated T cells. However, it is not a good proliferative factor for resting cells. Perhaps the failure of resting T cells to divide in response to IL-4 is because resting cells express proteins such as Dyrk, D52, TSC-22, and LKLF, which may be inhibitors of cell division (2124). If so, cell division by resting T cells may be, in a sense, actively inhibited by factors within the cell.

Activation caused an approximate doubling in the amount of total RNA per cell, and it is interesting to notice that expression of many of the RNAs in T cells increased concordantly when the cells were activated. This was very striking 48 hr after activation, a time when analysis showed that, in spite of the increase in RNA per cell, once the amounts of RNA per cell had been normalized, the levels of expression of many different genes in resting and activated T cells were the same. Such a result suggests that a global mechanism of transcription regulation was induced by T cell activation, increasing expression of many genes similarly. Such a global mechanism could involve components of the transcription apparatus, p53, or other proteins that concordantly regulate many populations of genes and/or mRNA stability (33, 34).

It is not surprising that many genes change in their level of expression after T cells had been activated for only 8 hr in animals. Perhaps this rapid response is, in part, due to the nature of the antigen we used. Superantigen does not need to be processed by antigen-presenting cells before it can interact with T cell receptors, and, therefore, T cell responses to such material probably will be a few hours faster than that of T cells to conventional protein antigens.

We were surprised to find that, although many genes increase in expression immediately after T cell activation, approximately the same number decrease. Thus, the variety of mRNAs in resting and activated T cells, as previously suggested (30), is about the same in magnitude. Again, such a result may reflect the recently appreciated high receptivity of resting T cells.

We did not expect to find that the mRNA content of T cells 48 hr after exposure to superantigen in animals would be more similar to that of resting T cells than to that of recently (8-hr) activated cells. Forty-eight hours after injection of superantigen, target T cells are still dividing vigorously, although they will stop dividing very shortly thereafter (data not shown). At 48 hr, the activated T cells are also about to die by apoptosis (16, 17), an event that we thought might involve induction of quite a few new genes. We have shown that exposure to reactive oxygen species is the major cause of the death of these cells (35). Nevertheless, we did not find increases in expression of any of the genes on the microarrays that code for proteins that might cause increases in reactive oxygen species concentrations.

There is the question of whether the kinetics and nature of the changes in gene expression that we report here, during T cell responses to superantigen, reflect the kinds of change that take place during T cell responses to conventional peptide antigens and/or infectious organisms. The kinetics of T cell responses to peptides and proteins administered in the absence of adjuvants are very similar to those of T cells responding to superantigens. Therefore, we believe that such responses will prove to be very similar to those described in this paper. Under nonlaboratory conditions, however, T cells usually encounter superantigens and conventional antigens in the presence of infections. Infectious organisms and laboratory adjuvants induce components of innate immunity. Such components directly or indirectly affect T cell responses such that the responses are larger in magnitude and the responding T cells are more long-lived (17, 36). Infectious agents therefore change gene expression in activated T cells, and the pattern of gene expression in activated T cells described in this paper thus probably is not identical to that which will be found in T cells activated in the presence of bacterial or viral products.

Acknowledgments

We thank Drs. Clive Slaughter and Steven Madden, University of Texas Southwestern Medical Center, Dallas, for their help in preparation of the cRNA samples, for conducting the Affymetrix gene array hybridizations, and for their patient advice afterward. We thank Drs. Louis Staudt, Gary Johnson, and James Hagman for reading the manuscript and for their very helpful suggestions. We also thank Bill Townend at the National Jewish Medical and Research Center for his help with cell sorting. This work was supported by Public Health Service Grants AI-17134, AI-18785, and AI-22295.

Abbreviation

SEB

staphylococcal enterotoxin B

References

  • 1.Zipfel P F, Irving S G, Kelly K, Siebenlist U. Mol Cell Biol. 1989;9:1041–1048. doi: 10.1128/mcb.9.3.1041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Zheng W, Flavell R A. Cell. 1997;89:587–596. [Google Scholar]
  • 3.Choi J W, Lee S Y, Choi Y. Cell Immunol. 1996;168:78–84. doi: 10.1006/cimm.1996.0051. [DOI] [PubMed] [Google Scholar]
  • 4.Liu A Y, Torchia B S, Migeon B R, Siliciano R F. Genomics. 1997;39:171–184. doi: 10.1006/geno.1996.4463. [DOI] [PubMed] [Google Scholar]
  • 5.Renner C, Pfitzenmeier J P, Gerlach K, Held G, Ohnesorge S, Sahin U, Bauer S, Pfreundschuh M. J Immunol. 1997;159:1276–1283. [PubMed] [Google Scholar]
  • 6.Ishaq M, Zhang Y M, Natarajan V. J Biol Chem. 1998;273:21210–21216. doi: 10.1074/jbc.273.33.21210. [DOI] [PubMed] [Google Scholar]
  • 7.Kirberg J, Berns A, von Boehmer H. J Exp Med. 1997;186:1269–1275. doi: 10.1084/jem.186.8.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Rooke R, Waltzinger C, Benoist C, Mathis D. Immunity. 1997;7:123–134. doi: 10.1016/s1074-7613(00)80515-4. [DOI] [PubMed] [Google Scholar]
  • 9.Tanchot C, Lemonnier F A, Perarnau B, Freitas A A, Rocha B. Science. 1997;276:2057–2062. doi: 10.1126/science.276.5321.2057. [DOI] [PubMed] [Google Scholar]
  • 10.Bender J, Mitchell T, Kappler J, Marrack P. J Exp Med. 1999;190:367–374. doi: 10.1084/jem.190.3.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Teague T K, Marrack P, Kappler J, Vella A T. J Immunol. 1997;158:5791–5799. [PubMed] [Google Scholar]
  • 12.Boise L H, Minn A J, June C H, Lindsten T, Thompson C B. Proc Natl Acad Sci USA. 1995;92:5491–5496. doi: 10.1073/pnas.92.12.5491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Akbar A N, Borthwick N J, Wickremasinghe R G, Panayoitidis P, Pilling P, Bonfill M, Krajewski S, Reed J C, Salmon M. Eur J Immunol. 1996;26:294–299. doi: 10.1002/eji.1830260204. [DOI] [PubMed] [Google Scholar]
  • 14.Vella A T, Dow S, Potter T A, Kappler J, Marrack P. Proc Natl Acad Sci USA. 1998;95:3810–3815. doi: 10.1073/pnas.95.7.3810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Boursalian T E, Bottomly K. J Immunol. 1999;162:3795–3801. [PubMed] [Google Scholar]
  • 16.Kawabe Y, Ochi A. Nature (London) 1991;349:245–248. doi: 10.1038/349245a0. [DOI] [PubMed] [Google Scholar]
  • 17.Vella A T, McCormack J E, Linsley P S, Kappler J W, Marrack P. Immunity. 1995;2:261–270. doi: 10.1016/1074-7613(95)90050-0. [DOI] [PubMed] [Google Scholar]
  • 18.Julius M H, Simpson E, Herzenberg L. Eur J Immunol. 1973;3:645–649. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  • 19.Kelly K, Siebenlist U. J Biol Chem. 1988;263:4828–4831. [PubMed] [Google Scholar]
  • 20.Torelli G, Selleri L, Donelli A, Ferrari S, Emilia G, Venturelli D, Moretti L, Torelli U. Mol Cell Biol. 1985;5:2874–2877. doi: 10.1128/mcb.5.10.2874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Becker W, Joost H G. Prog Nucleic Acid Res Mol Biol. 1999;62:1–17. doi: 10.1016/s0079-6603(08)60503-6. [DOI] [PubMed] [Google Scholar]
  • 22.Byrne J A, Nourse C R, Basset P, Gunning P. Oncogene. 1998;16:873–881. doi: 10.1038/sj.onc.1201604. [DOI] [PubMed] [Google Scholar]
  • 23.Kawamata H, Nakashiro K, Uchida D, Hino S, Omotehara F, Yoshida H, Sato M. Brit J Cancer. 1998;77:71–80. doi: 10.1038/bjc.1998.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Kuo C T, Veselits M L, Leiden J M. Science. 1997;277:1986–1990. doi: 10.1126/science.277.5334.1986. [DOI] [PubMed] [Google Scholar]
  • 25.Kahn-Perles B, Lipcey C, Lecine P, Olive D, Imbert J. J Biol Chem. 1997;272:21774–21783. doi: 10.1074/jbc.272.35.21774. [DOI] [PubMed] [Google Scholar]
  • 26.Jain J, Valge-Archer V E, Rao A. J Immunol. 1992;148:1240–1250. [PubMed] [Google Scholar]
  • 27.Chen F, Chen D, Rothenberg E. Int Immunol. 1999;11:677–688. doi: 10.1093/intimm/11.5.677. [DOI] [PubMed] [Google Scholar]
  • 28.Shin H M, Han T M. Mol Immunol. 1999;36:197–203. doi: 10.1016/s0161-5890(99)00030-9. [DOI] [PubMed] [Google Scholar]
  • 29.Sundstedt A, Dohlsten M. J Immunol. 1998;161:5930–5936. [PubMed] [Google Scholar]
  • 30.Alizadeh A, Eisen M, Botstein D, Brown P O, Staudt L M. J Clin Immunol. 1998;18:373–379. doi: 10.1023/a:1023293621057. [DOI] [PubMed] [Google Scholar]
  • 31.Hasegawa T, Takeuchi A, Miyaishi O, Isobe K, de Crombrugghe B. J Biol Chem. 1997;272:4915–4923. doi: 10.1074/jbc.272.8.4915. [DOI] [PubMed] [Google Scholar]
  • 32.Jung T M, Gallatin W M, Weissman I L, Dailey M O. J Immunol. 1988;141:4110–4117. [PubMed] [Google Scholar]
  • 33.Sauer F, Tijan R. Curr Opin Genet Dev. 1997;7:176–181. doi: 10.1016/s0959-437x(97)80126-8. [DOI] [PubMed] [Google Scholar]
  • 34.el-Deiry W S. Semin Cancer Biol. 1998;8:3445–3457. doi: 10.1006/scbi.1998.0097. [DOI] [PubMed] [Google Scholar]
  • 35.Hildeman D A, Mitchell T C, Teague T K, Henson P, Day B J, Kappler J, Marrack P. Immunity. 1999;10:735–744. doi: 10.1016/s1074-7613(00)80072-2. [DOI] [PubMed] [Google Scholar]
  • 36.Mitchell T, Kappler J, Marrack P. J Immunol. 1999;162:4527–4535. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES